Trials / Recruiting
RecruitingNCT05828225
Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of Refractory Myasthenia Gravis
A Study on the Safety and Efficacy of Chimeric Antigen Receptor T Cells in the Treatment of Refractory Myasthenia Gravis
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (estimated)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD19 CAR-T therapy for patients with refractory myasthenia gravis, and to evaluate the pharmacokinetics of CD19 CAR-T in patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CD19 CAR-T cells injection | CD19 CAR-T in the Treatment of Refractory Myasthenia Gravis |
Timeline
- Start date
- 2023-04-30
- Primary completion
- 2026-04-20
- Completion
- 2026-04-20
- First posted
- 2023-04-25
- Last updated
- 2023-04-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05828225. Inclusion in this directory is not an endorsement.